Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PAYO | 0.02% | $2.40B | +19.68% | 0.00% |
BVN | -0.09% | $4.10B | -4.72% | 0.00% |
SHOP | 0.11% | $147.45B | +72.07% | 0.00% |
GALT | -0.13% | $147.47M | +3.10% | 0.00% |
CREG | -0.22% | $5.81M | -77.49% | 0.00% |
CCJ | 0.26% | $31.90B | +48.92% | 0.15% |
MPAA | -0.26% | $196.30M | +63.70% | 0.00% |
LFWD | -0.38% | $7.77M | -83.29% | 0.00% |
QBTS | 0.40% | $4.38B | +1,129.82% | 0.00% |
NBIS | -0.42% | $12.34B | +173.71% | 0.00% |
FTNT | -0.46% | $78.92B | +71.08% | 0.00% |
VST | 0.51% | $66.18B | +126.84% | 0.45% |
K | -0.62% | $27.41B | +36.96% | 2.88% |
RLMD | 0.63% | $20.25M | -79.67% | 0.00% |
VLRS | 0.64% | $537.07M | -26.57% | 0.00% |
OXBR | -0.67% | $13.03M | -26.47% | 0.00% |
WRAP | 0.73% | $79.91M | -21.00% | 0.00% |
TH | -0.76% | $712.44M | -17.68% | 0.00% |
CMP | -0.85% | $833.66M | +93.90% | 0.00% |
VSTA | -0.93% | $342.46M | +40.00% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PFE | 56.64% | $137.53B | -13.55% | 7.04% |
BIIB | 54.99% | $18.47B | -45.61% | 0.00% |
TECH | 54.56% | $8.13B | -27.65% | 0.62% |
IQV | 54.49% | $27.24B | -25.53% | 0.00% |
TMO | 52.64% | $154.12B | -26.17% | 0.40% |
GSK | 52.22% | $78.10B | +0.21% | 4.17% |
ZTS | 50.44% | $69.53B | -9.92% | 1.20% |
RVTY | 49.75% | $11.53B | -6.71% | 0.29% |
ABBV | 49.60% | $322.03B | +6.29% | 3.50% |
LH | 48.85% | $21.80B | +28.05% | 1.10% |
GILD | 48.60% | $137.67B | +61.30% | 2.84% |
QGEN | 48.56% | $10.34B | +13.03% | 0.00% |
MTD | 48.55% | $24.62B | -15.24% | 0.00% |
NVS | 48.49% | $227.73B | +12.73% | 3.32% |
DHR | 47.52% | $142.28B | -20.43% | 0.73% |
LIN | 46.65% | $218.32B | +5.69% | 1.24% |
MEDP | 46.51% | $8.93B | -24.56% | 0.00% |
PEP | 45.99% | $179.67B | -20.55% | 4.19% |
KHC | 45.95% | $30.31B | -20.52% | 6.25% |
A | 45.77% | $33.85B | -8.07% | 0.81% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BBH | 72.68% | $329.40M | 0.35% |
FHLC | 68.79% | $2.42B | 0.084% |
XLV | 68.47% | $34.14B | 0.09% |
IYH | 68.23% | $2.71B | 0.39% |
VHT | 68.22% | $15.31B | 0.09% |
IXJ | 67.79% | $3.72B | 0.41% |
RSPH | 66.19% | $727.92M | 0.4% |
IBB | 64.92% | $5.36B | 0.45% |
PPH | 63.55% | $590.55M | 0.36% |
FXH | 63.12% | $898.02M | 0.62% |
FBT | 61.33% | $1.01B | 0.54% |
IHE | 60.82% | $557.07M | 0.39% |
PBE | 60.78% | $223.16M | 0.58% |
SCHD | 58.15% | $68.70B | 0.06% |
XPH | 56.99% | $149.79M | 0.35% |
HDV | 55.36% | $10.90B | 0.08% |
FDL | 55.32% | $5.39B | 0.43% |
FVD | 54.81% | $8.94B | 0.61% |
DHS | 54.47% | $1.22B | 0.38% |
USMV | 54.23% | $23.56B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XONE | 0.46% | $585.86M | 0.03% |
SHYM | -0.52% | $349.95M | 0.35% |
BOXX | -0.76% | $6.72B | 0.19% |
AGZD | 0.78% | $102.66M | 0.23% |
UGA | 0.79% | $72.51M | 0.97% |
USL | 0.96% | $42.26M | 0.85% |
DBA | 1.47% | $793.74M | 0.93% |
FXY | 1.49% | $815.67M | 0.4% |
FXE | -1.50% | $568.58M | 0.4% |
GBIL | -1.55% | $6.40B | 0.12% |
KCCA | -1.86% | $104.88M | 0.87% |
URNJ | 2.08% | $304.99M | 0.8% |
OILK | 2.08% | $71.89M | 0.69% |
URNM | 2.09% | $1.74B | 0.75% |
UUP | -2.16% | $237.02M | 0.77% |
WEAT | -2.25% | $117.15M | 0.28% |
IBDQ | 2.39% | $3.00B | 0.1% |
BNO | 2.42% | $103.68M | 1% |
IBTF | -2.65% | $2.02B | 0.07% |
SGOV | 2.83% | $49.84B | 0.09% |
Double maintains 15 strategies that include AMGN - Amgen, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BTCT | -20.43% | $18.98M | +37.85% | 0.00% |
MNOV | -12.99% | $65.23M | -7.64% | 0.00% |
HUSA | -10.53% | $22.94M | -6.82% | 0.00% |
SPTN | -8.22% | $897.34M | +41.31% | 3.31% |
MVO | -7.27% | $66.13M | -38.96% | 21.90% |
TLN | -6.44% | $13.56B | +168.31% | 0.00% |
DFDV | -5.92% | $247.94M | +1,821.34% | 0.00% |
AIFU | -5.62% | $6.13B | +82.50% | 0.00% |
ALAR | -5.40% | $90.19M | -69.19% | 0.00% |
RLX | -5.40% | $2.02B | +20.65% | 0.45% |
CLLS | -4.73% | $104.54M | -22.46% | 0.00% |
STG | -4.72% | $29.06M | -28.79% | 0.00% |
LRN | -4.53% | $6.34B | +106.55% | 0.00% |
HTZ | -4.32% | $1.00B | +100.28% | 0.00% |
VHC | -3.77% | $45.90M | +59.26% | 0.00% |
QNRX | -3.62% | $5.45M | -54.34% | 0.00% |
UUUU | -2.89% | $1.20B | -8.42% | 0.00% |
CEG | -2.72% | $100.35B | +59.87% | 0.46% |
TRVG | -2.42% | $82.60M | +79.60% | 0.00% |
SYPR | -2.23% | $52.86M | +19.79% | 0.00% |
Finnhub
By Connor Hart Amgen said a Phase 3 trial of its gastric cancer treatment, bemarituzumab, met its primary endpoint of overall survival at a pre-specified interim analysis. The biotechnology...
Finnhub
Amgen said on Monday itsexperimental therapy helped patients with advanced gastriccancer live longer when combined with chemotherapy, according tointerim data from a late-stage study. ...
Finnhub
Amgen said on Monday itsexperimental cancer therapy significantly improved overallsurvival in patients with advanced gastric cancer when combinedwith chemotherapy, marking a potential breakthrough...
Finnhub
Amgen said on Monday itsexperimental cancer therapy, when combined with chemotherapy,met the main goal in a late-stage trial. ...
Finnhub
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy AloneTHOUSAND OAKS, Calif., June 30, 2025...
SeekingAlpha
There are plenty of good strategies out there to invest. Check out how the BLSH strategy outperforms the S&P 500 with 14.5% annualized returns.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -28.92% | $165.69M | 0.85% |
TAIL | -24.61% | $99.76M | 0.59% |
CLIP | -18.83% | $1.52B | 0.07% |
ULST | -15.16% | $662.59M | 0.2% |
IVOL | -11.87% | $351.30M | 1.02% |
TPMN | -11.38% | $30.77M | 0.65% |
TFLO | -10.56% | $6.86B | 0.15% |
CANE | -9.82% | $10.44M | 0.29% |
XHLF | -6.83% | $1.73B | 0.03% |
BTAL | -5.21% | $296.79M | 1.43% |
CTA | -4.84% | $1.06B | 0.76% |
USDU | -4.32% | $162.92M | 0.5% |
FMF | -4.19% | $155.81M | 0.95% |
FTSD | -3.73% | $231.79M | 0.25% |
TBLL | -3.52% | $2.14B | 0.08% |
BIL | -3.23% | $42.87B | 0.1356% |
IBTF | -2.65% | $2.02B | 0.07% |
WEAT | -2.25% | $117.15M | 0.28% |
UUP | -2.16% | $237.02M | 0.77% |
KCCA | -1.86% | $104.88M | 0.87% |
Current Value
$278.851 Year Return
Current Value
$278.851 Year Return